Spexis AG

Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera

Spexis announces closing of sale of preclinical antibiotics program to Basilea

Spexis announces sale of preclinical antibiotics program to Basilea

Spexis is Granted Debt-Restructuring Moratorium

Spexis Provides Update Regarding Debt-Restructuring Moratorium

Spexis to file an application for a debt-restructuring moratorium

Spexis Announces Changes to the Executive Committee

Spexis to host business update conference call on October 9, 2023

Spexis provides business update and announces financial results for the first half of 2023

Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies

Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions

Spexis announces the results of its Annual General Meeting 2023

Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances

Spexis provides business update and announces financial results for the full year 2022

Spexis has received temporary approval of an extension until 31 of May 2023 for the disclosure obligation in connection with the publication and the filing of the annual report 2022.

Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study

Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin®

Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound

Spexis announces promising pre-clinical data with balixafortide in combination with various therapies on the market for treating B-cell lymphomas

Spexis to present at BIO-Europe® 2022

Spexis announces positive renal impairment clinical trial results with balixafortide

Spexis provides business update and announces financial results for the first half of 2022

Spexis announces presentation of half-year 2022 financial results and participation at upcoming industry and investor events in September

Spexis provides business update

Spexis announces business update call to be held on July 28th

Spexis announces business update call to be held on July 28th

Spexis’ CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical model

Spexis to present at H.C. Wainwright Global Investment Conference

Spexis to present at BioEquity Europe 2022